The popular explanation on these boards are that Nader (and board) has priced BP out of the picture. I'm sure there has been interest and DD done by many potential suitors, but for whatever reason they did not make an offer that we felt was best for the shareholders. The idea that Gilead and others don't know about us is ridiculous. This is about perceived value of the drug and the cost to acquire it. Is that Nader being unrealistic? Is he naive? Or is there something in the data/science that other companies don't feel will offer them a return on their investment.